Data Sheet (Cat.No.TMPY-03989)

TargetMol

PFDN1 Protein, Human, Recombinant (His)

General Information

Synonyms: PDF;PFD1;prefoldin subunit 1

Protein Construction: A DNA sequence encoding the human PFDN1 (NP_002613.2) (Met1-Gln122) was expressed with a polyhistide tag at the N-terminus. Predicted N terminal: His

Species: Human

Expression Host: E. coli

Accession: O60925

Molecular Weight: 16 kDa (predicted); 17 kDa (reducing conditions)

QC Testing

Biological Activity: Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.

Purity: > 95 % as determined by SDS-PAGE

Endotoxin: Please contact us for more information.

Formulation: Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, 10% Glycerol, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

PFDN1 expression positively correlated with tumor size and tumor invasion. The inhibitory effect of PFDN1 on tumor cell growth and motility was partially due to G2/M cell cycle blockage and cytoskeletal deficiency. PFDN1 was involved in the progression of CRC, and provide new insights into PFDN1 as a potential therapeutic target for colorectal cancer (CRC) treatment.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481